On April 13, 2021 Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and Brussels: KDS) reported that that a total of 95.03% of the Kiadis shares on a Fully Diluted basis have been tendered or irrevocably committed to be delivered to Sanofi at Settlement under the Offer by Sanofi (Press release, Sanofi, APR 13, 2021, View Source [SID1234577958]). Sanofi declares the Offer unconditional (doet gestand) now all Offer Conditions described in the Offer Memorandum have either been satisfied or waived. As a result of the adoption of the Post-Offer Restructuring Resolution at the Kiadis extraordinary meeting of shareholders ("EGM") of 30 March 2021, under the terms and subject to the conditions of the Offer, the Acceptance Threshold is 80% (and not 95%) of Kiadis’ aggregate issued and outstanding ordinary share capital on a Fully Diluted basis, as of the time and date on which the Offer expires.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Acceptance
During the Acceptance Period, that expired at 17:40 (CET) on 12 April 2021, 39,860,388 Shares were tendered under the Offer, representing approximately 92.9% of the aggregate issued and outstanding ordinary share capital of Kiadis as of today and an aggregate value of approximately
EUR 217,239,114.60 (for an Offer Price of EUR 5.45 (cum dividend) per Share). Together with any Shares directly or indirectly owned by Sanofi, the Offeror or any of their Affiliates, any Shares irrevocably committed to be delivered to Sanofi at settlement of the Offer and any Shares to which the Offeror Group is entitled but which have not yet been delivered (gekocht maar nog niet geleverd), this represents a total of 58,051,156 Shares. This equals approximately 95.03% of the aggregate issued and outstanding ordinary share capital of Kiadis on a Fully Diluted basis.

Settlement
With reference to the Offer Memorandum, Shareholders who accepted the Offer shall receive the Offer Price for each Tendered Share tendered during the Acceptance Period and transferred (geleverd) for acceptance pursuant to the Offer, under the terms and conditions of the Offer and subject to its restrictions.

Settlement of the Shares and payment of the Offer Price will take place on 16 April 2021. Following Settlement, the Offeror will (directly or indirectly) hold 58,051,156 Shares, representing approximately 95.03% of the aggregate issued and outstanding ordinary share capital of Kiadis on a Fully Diluted basis.

Upon Settlement the changes to the composition of the Supervisory Board and Management Board of Kiadis, as approved by the EGM on 30 March 2021, will become effective.

Post-Closing Acceptance Period
The Offeror hereby announces that Shareholders who have not tendered their Shares during the Acceptance Period will have the opportunity to tender their Shares under the same terms and conditions applicable to the Offer, during the Post-Closing Acceptance Period which will start at 09:00 (CET) on 14 April 2021 and end at 17:40 (CET) on 28 April 2021 (the "Post-Closing Acceptance Period").

The Offeror will publicly announce the results of the Post-Closing Acceptance Period and the total number and total percentage of Shares held by it in accordance with Section 17, paragraph 4 of the Decree ultimately on the third Business Day following the last day of the Post-Closing Acceptance Period.

The Offeror shall continue to accept for payment all Shares validly tendered (or defectively tendered provided that such defect has been waived by the Offeror) during the Post-Closing Acceptance Period and shall pay for such Shares as soon as reasonably possible and in any case no later than on the fifth Business Day following the last day of the Post-Closing Acceptance Period.

During the Post-Closing Acceptance Period, Shareholders have no right to withdraw Shares from the Offer, regardless of whether their Shares have been validly tendered (or defectively tendered, provided that such defect has been waived by the Offeror) during the Offer Period or the Post-Closing Acceptance Period.

Delisting
The Offeror and Kiadis shall seek to procure the delisting of the Shares on Euronext Amsterdam and Euronext Brussels as soon as possible under Applicable Rules. Delisting may further adversely affect the liquidity and market value of any Shares not tendered.

Further implications of the Offer being declared unconditional
Remaining Shareholders who do not wish to tender their Shares in the Post-Closing Acceptance Period should carefully review the sections of the Offer Memorandum that further explain the intentions of the Offeror, such as (but not limited to) Section 6.11 (Consequences of the Offer for non-tendering Shareholders), which describes certain implications to which such Shareholders may become subject with their continued shareholding in Kiadis.

The Offeror intends to initiate the Buy-Out in an expeditious manner. Reference is made to section 6.11(c) (Buy-Out) of the Offer Memorandum.

Announcements
Any announcement contemplated by the Offer Memorandum will be issued by press release. Any press release issued by the Offeror will be made available on the website of the Offeror (www.sanofi.com). Any press release issued by Kiadis will be made available on the website (www.kiadis.com).

Subject to any applicable requirements of the applicable rules and without limiting the manner in which the Offeror may choose to make any public announcement, the Offeror will have no obligation to communicate any public announcement other than as described above.

Offer Memorandum, Position Statement and further information
This announcement contains selected, condensed information regarding the Offer and does not replace the Offer Memorandum and/or the Position Statement. The information in this announcement is not complete and additional information is contained in the Offer Memorandum and the Position Statement.

Digital copies of the Offer Memorandum are available on the website of the Offeror (www.sanofi.com) and digital copies of the Position Statement are available on the website of Kiadis (www.kiadis.com). Such websites do not constitute part of, and are not incorporated by reference into, the Offer Memorandum. Copies of the Offer Memorandum and the Position Statement are on request also available free of charge at the offices of Kiadis and the Settlement Agent at the addresses below

On April 13, 2021 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company reported that IMV’s executive management team will be participating in the 2021 Bloom Burton & Co. Healthcare Investor Virtual Conference which will be held April 20 and April 21, 2021 (Press release, IMV, APR 13, 2021, View Source [SID1234577956]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IMV’s presentation details include:

Date: Tuesday, April 20, 2021
Time: 4:00 p.m. ET
There will be a live webcast of IMV’s presentation accessible in the ‘Events, Webcasts & Presentations’ page of IMV’s website. The webcast will then be archived following the live presentation and a copy of the presentation will be available www.imv-inc.com.

On April 13, 2021 Cofactor Genomics, the company bridging the precision medicine gap, reported commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company’s patented approach to generating multidimensional immune biomarkers (Press release, Cofactor Genomics, APR 13, 2021, View Source [SID1234577954]). Fifteen hospitals and healthcare networks, including Mayo Clinic, MultiCare Institute for Research and Innovation, and Revive Research Institute, are currently enrolling in the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial to evaluate use of the OncoPrism test in patients with recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) to effectively predict a patient’s response to immunotherapy. The company expects additional sites to join the trial before the end of 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While the trial will initially recruit RM-HNSCC patients, the protocol is approved for recruitment of patients with 10 additional indications where independent market research has identified an unmet clinical need in predicting tumor response to immunotherapy. Specimens collected in the study will be analyzed at Cofactor’s CAP/CLIA accredited laboratory.

"Opening recruitment for the PREDAPT study is a significant milestone for Cofactor. It represents not only the world’s first Predictive Immune Modeling clinical validation study, but the first of many studies we intend to sponsor. These studies will lead to predictive diagnostics that are undeniably needed in the field, for therapies that are in development or those already on the market," stated David Messina, PhD, Cofactor’s Chief Operating Officer. "Physicians do not currently have adequate information to predict tumor response to immune checkpoint inhibitors, resulting in ineffective and inconsistent treatment. This is ultimately a heavy burden on both patients and the healthcare system that supports them; we intend to change that."

The study includes both retrospective and prospective specimen collection, but does not require any additional visits or surgery outside of standard care for enrolled patients. The PREDAPT trial builds on preliminary results recently presented that showed the performance of a multidimensional RNA biomarker built using the company’s Predictive Immune Modeling approach was more effective than the on-label PD-L1 immunohistochemistry (IHC) assay in predicting tumor response to anti-PD-1 therapy in RM-HNSCC.

PREDAPT is uniquely designed to be a decentralized study. To enable that, Cofactor has contracted Curebase as the CRO partner, who enables highly virtual clinical trials by offering a full-service CRO and eClinical Platform, complete with eConsent, electronic data capture, and remote monitoring capabilities. This enables individual investigators, who may be passionate about science and improving patient outcomes, the ability to participate in the clinical trial even if their hospital is unable to participate as a traditional clinical site. It has also enabled Cofactor to establish two major recruitment streams to ensure maximum diversity and streamlined recruitment, traditional clinical sites and direct-to-patient recruitment.

"The PREDAPT study is exactly what we had in mind when we built the Curebase platform. Using software-powered, decentralized research methods, we are proving with Cofactor that any patient can be part of a clinical trial no matter where they live," noted Tom Lemberg, CEO at Curebase.

Despite the thousands of new clinical trials that are started every year and the significant advances made in launching innovative therapies such as immunotherapies, physicians are still prescribing the wrong therapy to more than 80 percent of patients.1 The gap in matching these innovative therapies to the patients that will benefit (and avoiding those who will not respond or may have adverse reactions) is a major problem in healthcare.

"Technologies that are capable of playing matchmaker and bridging this gap are key," said Jarret Glasscock, PhD, Cofactor’s Chief Executive Officer. "The field of Predictive Immune Modeling is building this next generation of predictive diagnostics that are showing an enhanced ability to accurately predict patient response prior to treatment. We expect these technologies to not only improve patient treatment paths, but to also provide cost savings to the entire healthcare system."

Sites interested in joining this high impact study may contact [email protected] or express their interest here.

On April 13, 2021 Herantis Pharma Plc ("Herantis"), focusing on disease modifying therapies for debilitating neurodegenerative diseases, reported that Dr. Craig Cook, Chief Executive Officer, will hold 1×1 meetings and have a digital company presentation in the upcoming Nordic Life Science Days conference (Press release, Herantis Pharma, APR 13, 2021, View Source,c3324050 [SID1234577949]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event Details:

Nordic Life Science Days Digital

Dates: 20 – 23 April 2021

On 20 April 2021 all presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at the Nordic Life Science Days if you wish to attend.

On April 13, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) reported that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY) (Press release, Evotec, APR 13, 2021, View Source;announcements/p/evotec-launches-belab2122-translating-academic-innovation-from-leading-german-life-science-region-in-collaboration-with-bristol-myers-squibb-6047 [SID1234577948]). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LET’S CALL EVOTEC | THOMAS HANKE ON BELAB2122 AND BRIDGES

Mediated and supported by BioRN, the Life Science Cluster Rhein Neckar, beLAB2122 for the first time brings together the European Molecular Biology Laboratory ("EMBL"), the German Cancer Research Center ("DKFZ"), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen in one collaboration with industry partners. Evotec’s BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaborations provide an integrated fund and award framework to validate exciting academic projects in collaborations with pharma and funders which may lead to the formation of jointly owned new companies. Since 2016, Evotec has established several BRIDGE collaborations with a variety of academic, pharma, and venture capital partners across Europe and North America.

Evotec launches beLAB2122 in cooperation with Bristol Myers Squibb, Evotec’s long-standing collaborator in drug discovery across several therapeutic areas. Together the sponsors intend to tap into Europe’s foremost academic clusters of excellence in the life sciences, both validating and advancing innovative research in therapeutics and related technologies from academia to enable the formation of new, collectively owned spin-out companies.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "We are very excited about the launch of beLAB2122, a truly transformative framework that leverages first-class science from one of Europe’s leading life science cluster regions with lots of potential to generate medical progress. We look forward to unlocking this potential by using our ‘data-driven R&D Autobahn to Cures’ to further validate and develop these approaches to translate the promising early-stage research into the medicines of the future."

Dr Thomas Hanke, Head of Academic Partnerships at Evotec, added: "We are delighted to see the first BRIDGE in Germany becoming reality and look forward to working closely with our academic partners in the Rhine-Main-Neckar area and our colleagues at Bristol Myers Squibb to identify and accelerate the next generation of first-in-class therapeutics across all modalities and therapeutic areas. We would also like to particularly thank BioRN for continuously supporting beLAB2122."

Dr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb commented: "We are excited by the opportunity to support beLAB2122 in the translation of novel scientific research from these leading German academic institutions. Given their past experience with successful BRIDGEs, we believe Evotec is well-equipped to interpret the many lines of scientific inquiry resulting from this collaboration and use its proprietary platforms to deliver quality data that may one day lead to potentially novel therapies for patients."

Prof. Matthias Hentze, EMBL Director, said: „This collaboration has been established at a time of increasing awareness that the efficient and rapid translation of research outcomes is essential. beLAB2122 is a transformative collaboration to accelerate the validation of therapeutic concepts for the benefit of society. EMBL, as Europe’s leading molecular biology research institute, is delighted to be part of this initiative along with some of the most renowned institutes in the region and beyond. With Evotec and Bristol Myers Squibb this collaboration has world-renowned industrial sponsors to help bring successful ideas into the market and to foster cutting-edge research and innovation."

Dr Rainer Wessel, Chief Innovation Officer, German Cancer Research Center (DKFZ), added: "For DKFZ, a major goal is to foster transfer of our excellent research into highly innovative applications that benefit cancer patients world wide. The beLAB2122 collaboration is a major step in gaining critical mass and speed together with other scientific and commercial leaders to achieve that goal."

Prof. Dr Manfred Schubert-Zsilavecz, Vice President of Goethe University Frankfurt responsible for the Third Mission and Professor for Medicinal Chemistry, pointed out: "Pharmaceutical and translational medical research are two of the key strengths of Goethe University Frankfurt, and numerous of our research projects aim to contribute to closing the innovation gap in drug development. We are extremely happy to be part of the beLAB2122 research network in order to boost cooperation between academic and industrial research, for the sake of suffering patients."

Prof. Dr Matthias Weidemüller, Vice-Rector Innovation and Transfer, Heidelberg University, affirmed: "Heidelberg University is excited to be part of the Evotec BRIDGE collaboration beLAB2122. It is of fundamental importance that our cutting-edge research be translated into applications on a broader scale. This collaboration brings together leading institutions in the Rhine-Main-Neckar region that conduct research at the forefront of life science. I am positive that – within the BRIDGE framework – we can generate added momentum for converting scientific achievements into future therapeutics."

Prof. Dr Peter Grathwohl, Vice-President of Research and Innovation of the University of Tübingen, joined: "The University of Tübingen is delighted to be part of beLAB2122. The transfer of research results to application is very important to us: In the future, we want to provide excellent opportunities for our researchers to contribute their expertise to concrete collaboration projects with sponsors in economy and industry."

The name beLAB2122 refers to the Rhine, Main, and Neckar rivers which connect the member institutions with one another and which total 2,122 kilometres in length. For further information on beLAB2122, please visit www.belab2122.org.